^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Esophageal Adenocarcinoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/29/2023
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers: Adenocarcinoma…Preferred Regimens…MSI-H/dMMR tumors (independent of PD-L1 status)…Pembrolizumab...Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and pembrolizumab…
    Secondary therapy:
    5-fluorouracil + oxaliplatin; capecitabine + oxaliplatin
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Small Intestinal Carcinoma)
    New
    Title:

    European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Tumors in Five Different Types of Cancer

    Excerpt:
    Merck...announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors in adults with...unresectable or metastatic gastric, small intestine or biliary cancer, who have disease progression on or following at least one prior therapy.